View options
Result details

Results per page
Articles per page View Sort by

3 results matched your search query
Keywords = Radiation

  • Open Access Research Article
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2018, 3(2), 60-68. http://doi.org/10.31586/Cancer.0302.01
    151 Views 32 Downloads 3 Shares PDF Full-text (3.365 MB)  HTML Full-text
    Abstract
    Objective: To evaluate the efficacy and safety of nimotuzumab in combination with radiochemotherapy as the primary treatment in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Methods: We retrospectively reviewed patients with locoregionally advanced nasopharyngeal carcinoma from September 2012 to December 2016. 188 newly diagnosed patients with stage III?IVB nasopharyngeal carcinoma
    [...] Read more.
    Objective: To evaluate the efficacy and safety of nimotuzumab in combination with radiochemotherapy as the primary treatment in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Methods: We retrospectively reviewed patients with locoregionally advanced nasopharyngeal carcinoma from September 2012 to December 2016. 188 newly diagnosed patients with stage III?IVB nasopharyngeal carcinoma were treated with at least 1-2 cycles of chemotherapy concurrently with planned IMRT. 88 patients received nimotuzumab 200 mg/week. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of Radiation Therapy Oncology Group. Results: After 3 months of treatment, the complete response rates of nasopharyngeal tumors in the study group and the control group were 78.4% and 65.5%, respectively (?2=4.070, P=0.044). The total complete response rates of cervical lymph nodes in the study group and the control group were 80.7% and 67.6% respectively (?2=4.022, P=0.045).The median cycle for nimotuzumab addition was 6.3 weeks. With a median follow-up of 36.3 months (range, 12?72 months), the estimated 3-year progression failure-free survival and overall survival rates for the study group and the control group were 85.24% vs 81.97% and 96.67% vs 90.0%, respectively. The 3-year local recurrence-free survival rates for the study group and the control group were 96.67% vs 83.60%, respectively (P=0.047). Grade 3 radiation-induced mucositis accounted for 36.4% of treated patients. No skin rash and infusion reaction were observed, distinctly from what is reported in control patients. Conclusion: Nimotuzumab plus chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma showed promising outcomes in terms of locoregional control, without increasing the incidence of radiation-related toxicities for patients.  Full article
    Figures

    Figure 1 of 1

    References
    [1]
    Tang LL, Chen WQ, Xue WQ, He YQ, Zheng RS, ZengYX, Jia WH. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett. 2016; 374:22?30.
    [2]
    Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12?22.
    [3]
    Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, TangLL, Lin AH, Li L, Ma J. The seventh edition of UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity modulated radiotherapy from an endemic area in China. Radiother Oncol. 2012;104:331-337.
    [4]
    Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, Siu L, Ng WT, Sze WK, Au GK, Law SC, O?Sullivan B, Yau TK, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010; 102:1188?98.
    [5]
    Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012; 23:427?35.
    [6]
    Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012; 48:1038?44.
    [7]
    Baujat B, Audry H, Bourhis J, Chan AT, Onat H, ChuaDT, Kwong DL, Al-Sarraf M, Chi KH, HareyamaM,Leung SF, Thephamongkhol K, Pignon JP, and MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta analysisof eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006; 64:47?56.
    [8]
    Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51: 2587-95.
    [9]
    Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kongexperience. Int J Radiat Oncol Biol Phys. 2005; 61: 1107-16.
    [10]
    Wu F, Wang R, Lu H, Wei B, Feng G, Li G, et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multi centric clinical study. Radiother Oncol. 2014; 112:106?11.
    [11]
    Vallath S, Hynds RE, Succony L, Janes SM, Giangreco A. Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J. 2014,44:513?522.
    [12]
    Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014; 50:498?505.
    [13]
    Wang SS, Guan ZZ, Xiang YQ, Wang B, Lin TY, Jiang WQ, et al. Significance of EGFR and p-ERK expression in nasopharyngeal carcinoma. Chin J Oncol?2006,28?1??28-31.
    [14]
    Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):11?20.
    [15]
    Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors incancer treatment: advances, challenges and opportunities. Anti-Cancer Drugs. 2009;20(10):851?5.
    [16]
    Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004; 22:1646-54.
    [17]
    Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005,7:575?589.
    [18]
    Cuneo KC, Nyati MK, Ray D, Lawrence TS. EGFR targeted therapies andradiation: optimizing efficacy by appropriate drug scheduling and patients election. Pharmacol Ther. 2015;154:67-77.
    [19]
    Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, GarridoG,Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69(14):5851?9.
    [20]
    Huang XD, Yi JL, Gao L, Xu GZ, Jin J, Yang WZ, Lu TX, Wu SX, Wu RH, Hu WH, Xie WC, Han F, Gao YH, Gao JM, Pan JJ, Chen CB, Lang JY, Li T, Dong Y, Fu, YB, Fan L, Li BS, Li J, Wang XH, Chen BX, Gao XS, Zhang P, Wu XW, Hu BQ. Multi-center phase 2 clinical trial of humanized anti-epidernal fator receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma . Chin J Oncol?2007, 29?3??197-200.
    [21]
    HM Li, P Li, YJ Qian, et al. A retrospective paired study: efficacy andtoxicity of nimotuzumab versus cisplatinconcurrent with radiotherapy innasopharyngeal carcinoma. BMC Cancer (2016) 16:946.
    [22]
    F Wang, C Jiang, Z Ye, Q Sun, T Liu, M Xu, et al. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oncotarget, 2017, 8: 75544-75556.
    [23]
    R You, YJ Hua, YP Liu, et al. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. Theranostics 2017, 7:2314-2324.
    [24]
    R Zhai, H Ying, F Kong, et al. Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Onco Targets and Therapy 2015:8 3383?3390.
    [25]
    F Wang, C Jiang, Z Ye, T Liu, F Yan, L Wang, et al. Long-Term Use of Nimotuzumab in Combination with Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution. Onco Res, 2017, 26:277-287.
    [26]
    Z Li, Y Li,S Yan, J Fu, Q Zhou, X Huang, et al. Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma. OncoTargets and Therapy 2017:10 5445?5458.
    [27]
    WMA, World Medical Association. Declaration of Helsinki. J Am Med Assoc. 2013;227:925?26.
  • Open Access Mini Review
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2014, 1(1), 26-27. http://doi.org/10.31586/Radiotherapy.0101.04
    223 Views 205 Downloads PDF Full-text (280.622 KB)  HTML Full-text
    Abstract
    Dose calculations based on Monte Carlo (MC) often require sophisticated treatment planning stations with long processing time, and this could be issue for many cancer centers. Hence, most of the commercial treatment planning system include faster dose calculation engines for the daily clinical routine. Due to advancement in technology and
    [...] Read more.
    Dose calculations based on Monte Carlo (MC) often require sophisticated treatment planning stations with long processing time, and this could be issue for many cancer centers. Hence, most of the commercial treatment planning system include faster dose calculation engines for the daily clinical routine. Due to advancement in technology and computing power, it is now possible to implement MC based dose calculation algorithms in the clinical environment. This report summarizes the major findings of various researchers who have investigated Acuros XB algorithm, which is the MC based dose calculation algorithm commercially available for dose calculations in radiotherapy.  Full article
    References
    [1]
    Lu L. Dose calculation algorithms in external beam photon radiation therapy. Int J Cancer Ther Oncol 2013; 1(2):01025.
    [2]
    Han T, Followill D, Mikell J, Repchak R, Molineu A, Howell R, Salehpour M, Mourtada F. Dosimetric impact of Acuros XB deterministic radiation transport algorithm for heterogeneous dose calculation in lung cancer. Med Phys. 2013; 40(5):051710.
    [3]
    Kan MW, Leung LH, So RW, Yu PK. Experimental verification of the Acuros XB and AAA dose calculation adjacent to heterogeneous media for IMRT and RapidArc of nasopharygeal carcinoma. Med Phys. 2013 Mar; 40 (3): 031714.
    [4]
    Stathakis S, Esquivel C, Quino L, Myers P, Calvo O, Mavroidis P, Guti?rrez A and Papanikolaou P. Accuracy of the Small Field Dosimetry Using the Acuros XB Dose Calculation Algorithm within and beyond Heterogeneous Media for 6 MV Photon Beams. Int Jour of Med Phys Clin Eng Radiat Onc 2012; 1 (3): 78-87.
    [5]
    Ojala JJ, Kapanen MK, Hy?dynmaa SJ, Wigren TK, Pitk?nen MA. Performance of dose calculation algorithms from three generations in lung SBRT: comparison with full Monte Carlo-based dose distributions. J Appl Clin Med Phys. 2014; 15(2):4662.
    [6]
    Kroon PS, Hol S, Essers M. Dosimetric accuracy and clinical quality of Acuros XB and AAA dose calculation algorithm for stereotactic and conventional lung volumetric modulated arc therapy plans. Radiat Oncol. 2013; 8(1):149.
    [7]
    Kathirvel M, Subramanian S, Clivio A, et al. Critical appraisal of the accuracy of Acuros-XB and Anisotropic Analytical Algorithm compared to measurement and calculations with the compass system in the delivery of RapidArc clinical plans. Radiat Oncol 2013; 8:140.
    [8]
    Liu HW, Nugent Z, Clayton R, Dunscombe P, Lau H, Khan R. Clinical impact of using the deterministic patient dose calculation algorithm Acuros XB for lung stereotactic body radiation therapy. Acta Oncol. 2013 Aug 19. [Epub ahead of print]
    [9]
    Fogliata A, Nicolini G, Clivio A, Vanetti E, Cozzi L. Critical appraisal of Acuros XB and Anisotropic Analytic Algorithm dose calculation in advanced non-small-cell lung cancer treatments. Int J Radiat Oncol Biol Phys. 2012; 83(5):1587-95.
    [10]
    Rana S. Clinical dosimetric impact of Acuros XB and analytical anisotropic algorithm (AAA) on real lung cancer treatment plans: review. Int J Cancer Ther Oncol 2014; 2(1):02019.
    [11]
    Ojala J. The accuracy of the Acuros XB algorithm in external beam radiotherapy ? a comprehensive review. Int J Cancer Ther Oncol 2014; 2(4):020417.
    [12]
    Chetty IJ, Curran B, Cygler JE, et al. Report of the AAPM Task Group 105: Issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning. Med Phys. 2007; 34(12):4818?53.
  • Open Access Research Article
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2014, 1(1), 38-48. http://doi.org/10.31586/Biochemistry.0101.06
    178 Views 265 Downloads 1 Citations PDF Full-text (962.717 KB)  HTML Full-text
    Abstract
    The biological activity of chemical compounds is analyzed using electronic and information factors. We found a linear interrelation between the electronic and information factors of molecules. Moreover, these molecular factors are calculated from different principles. Electronic factor is determined by the quantum-mechanical method from the molecular pseudopotential, whereas the information
    [...] Read more.
    The biological activity of chemical compounds is analyzed using electronic and information factors. We found a linear interrelation between the electronic and information factors of molecules. Moreover, these molecular factors are calculated from different principles. Electronic factor is determined by the quantum-mechanical method from the molecular pseudopotential, whereas the information factor is determined by using the information function. It is shown that these factors are separated off statistically significant bioactive chemical compounds of inactive chemicals. To determine these factors is sufficient to know only the chemical formula of molecules. We analyzed the chemical compounds for toxicity, antiradiation activity, carcinogenicity, antifungal activities. To identify biologically active chemical compounds we used the statistical conjugation method of qualitative attributes.  Full article
    Figures

    Figure 6 of 8

    References
    [1]
    Bacq Z.M., Alexander P. (1961). Fundamentals of Radiobiology. Pergamon Press, Oxford ? New-York ? Paris.
    [2]
    Veljkovi? V., Lalovi? D. (1973). General model pseudopotential for positive ions. Phys. Lett., 45A, 59-60.
    [3]
    Mukhomrov V.K. (2014). Biological Activity of Chemical Compounds and their Molecular Structure ? Information Approach. J. Chem. Eng. Chem. Res., 1(1), 54-65.
    [4]
    Veljkovi? V., Lalovi? D. (1977). Experienta, 33(9), 1228.
    [5]
    Sweeney T.R. (1979). Survey of compounds from the antiradiation drug development programm. Washington.
    [6]
    Romantzev, E.F. (1968). Radiation and chemical protection. Nauka, Moscow, 1968 (in Russian).
    [7]
    F?rster E., R?nz B. (1979). Methoden der Korrelations- und Regressionsanalyse. Verlag Die Wirtschaft. Berlin.
    [8]
    Shannon C. (1948). A Mathematical Theory of Communications. Bell Syst. Techn. Journal. 27, 379-423.
    [9]
    Kolmogorov A.N. (1987). Information Theory and Theory of Algotithms. Nauka. Moscow. (in Russian).
    [10]
    Pustyl?nik E.I. (1968). Statistical Methods of Analysis and Processing Observations. Nauka, Moscow. (in Russian).
    [11]
    Westland R.D. (1968). N-Substituted S-2 Aminoethyl Thiosulfates as Antiradiation agents. J. Med. Chem. 11, 1190-1201.
    [12]
    Mukhomorov V.K. (2013). Linking the Radio-Protective Effects of Tryptamine Analogues with their Electronic and Steric Properties via Quantum Mechanics Calculations. Chem. Rapid Commun. 1(1), 15-20.
    [13]
    Turusov, V.S. (1964). Cancerogenic Substances. Handbook. Nauka, Moscow, (in Russian).
    [14]
    Belenkaya I.A., Dyachina Zh.S., Mukhomorov V.K. (1991). Structure-Activity. Association of the Electronic Parameters of Substituted Benzo-2,1,3-Thia- and Selenadiazoles with their Antifungal Activity and Toxicity. Pharm. Chem. Journal.. 25(12), 900-906.
    [15]
    Golyshin N.M. (1970). Fungitsidy v sel'skom khozyaystve (Fungicides in Agriculture). M. (in Russian).
Filter options
Publication Date
From to
Refine Publication Date
Subject Areas
Refine Subjects
Article Types
Refine Article Types
Countries / Territories
Refine Countries / Territories